Depressive symptoms and non-adherence to treatable cardiovascular risk factors' medications in the CONSTANCES cohort

Nadine Hamieh1, Sofiane Kab2, Marie Zins2,3

  • 1Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Équipe de Recherche en Épidémiologie Sociale, Paris F75012, France.

Insights

Depression is linked to cardiovascular disease (CVD), but poor medication adherence is not a major explanation. Depression may impact adherence to diabetes medications early in treatment.

Area of Science:

  • Cardiology
  • Psychiatry
  • Public Health

Background:

  • Depression is a known risk factor for cardiovascular disease (CVD).
  • The role of medication non-adherence in the depression-CVD link is not well understood.
  • Understanding this relationship is crucial for managing cardiovascular risk factors.

Purpose of the Study:

  • To investigate the association between depressive symptoms and medication non-adherence.
  • To examine adherence to medications for type 2 diabetes, hypertension, and dyslipidemia in relation to depression.
  • To clarify the contribution of non-adherence to the depression-CVD association.

Main Methods:

  • Prospective study using the French CONSTANCES cohort and national healthcare data.
  • Assessed depressive symptoms using the Center for Epidemiological Studies Depression scale.
  • Tracked medication adherence (dispensed drugs) over 36 months for diabetes, hypertension, and dyslipidemia treatments.

Main Results:

  • Depressive symptoms were not significantly associated with non-adherence to hypertension, diabetes, or dyslipidemia medications over 36 months.
  • A significant association was found between depressive symptoms and non-adherence to anti-diabetic medications within the first 3-6 months.
  • Overall non-adherence rates were slightly higher in depressed individuals but not statistically significant after adjustments.

Conclusions:

  • Medication non-adherence is unlikely to be a primary driver of the association between depression and CVD.
  • Clinicians should screen for and treat depression in individuals with diabetes to improve medication adherence.
  • Targeted interventions for early-stage diabetes medication adherence in depressed patients may be beneficial.
Abstract

Related Concept Videos

Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
617
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
111
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
486
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
193
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
201
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
691